This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Emerging Biological Therapies for Psoriasis: Promising Efficacy of Interleukin-17 (IL-17) and IL-23 Pathway Inhibitors

Emerging Biological Therapies for Psoriasis: Promising Efficacy of Interleukin-17 (IL-17) and IL-23 Pathway Inhibitors

Format

Webcast

Time to Complete

1 hour

Released

October 28, 2016

Expires

October 28, 2017
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Jointly provided by A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet

Commercial Supporter

Supported by Lilly USA, LLC and Janssen Scientific Affairs, LLC

Program Description

This webcast is intended to improve care of patients with psoriasis by accelerating adoption of new guidelines and evidence-based practice change. In addition to chemotherapy, this enduring webcast will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is directed primarily to dermatologists and health care professionals involved in the treatment and management of patients with psoriasis. No specific skill or knowledge other than a basic training in medicine is required for successful participation in this activity.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Assess diagnostic criteria and standard treatment options for early and moderate to severe patients with psoriasis
  • Integrate newer biological therapy with interleukin-17 (IL-17) and IL-23 pathway inhibitors in patients with moderate to severe psoriasis

Conflict Of Interest Disclosure Policy

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

Neil Korman, MD, PhD
Professor of Dermatology
CWRU School of Medicine
Director
Clinical Trials Unit, UH Case Medical Center
Director
Murdough Family Center for Psoriasis
UH Case Medical Center
Cleveland, OH

Dr. Korman discloses the following:
Consultant: AbbVie, Amgen, Celgene, Lilly USA, LLC, Janssen, Merck, Novartis, and Pfizer

Anthony Fernandez, MD, PhD
Director of Medical Dermatology
Departments of Dermatology Pathology
Cleveland Clinic
Cleveland, OH

Dr. Fernandez discloses the following:
Speaker’s Bureau: AbbVie, Celgene
Advisory Board Member: AbbVie
Research Support: Mallinkrodt, Roche, AbbVie, and Xoma

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Neil Korman, MD, PhD, discloses that he is a consultant for AbbVie, Amgen, Celgene, Lilly USA, LLC, Janssen, Merck, Novartis, and Pfizer.

Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating in or receiving credit for this webcast. During the period October 28, 2016 through October 28, 2017, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

A. Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue